Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22404
Title: Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.
Authors: Nolan, Brendan;Varadarajan, Suresh;Fourlanos, Spiros;Neoh, Sandra L
Affiliation: Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Department of Endocrinology, Northern Hospital, Epping, Victoria, Australia
Issue Date: 7-Jan-2020
EDate: 2020
Citation: The American journal of medicine 2020; online first: 7 January
Abstract: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are increasingly used for the treatment of type 2 diabetes but have been associated with ketoacidosis. We report a case series of three patients with latent autoimmune diabetes who presented with ketoacidosis, including one case with normal blood glucose levels, in the context of SGLT2 inhibitor use. SGLT2 inhibitors should only be used with caution and close clinical monitoring in patients with latent autoimmune diabetes. A clinical risk score permits targeted autoantibody testing and should be undertaken prior to commencement of SGLT2 inhibitors and/or cessation of insulin.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22404
DOI: 10.1016/j.amjmed.2019.12.006
PubMed URL: 31923401
Type: Journal Article
Subjects: SGLT2 inhibitor
diabetes
diabetic ketoacidosis
latent autoimmune diabetes
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.